– Seeking inclusion of CV risk reduction indications in Europe – – Anticipated approvals in Europe in the first half of 2024 – ANN ARBOR, Mich., June 28, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that the application was filed for a Type II(a) variation with the European Medicines Agency (EMA) […]
Other News
Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America
Liquidia exclusively licenses North American rights to L606, an inhaled formulation of treprostinil administered twice-daily with a short duration, next-generation nebulizer Liquidia funds $10 million upfront payment from finance agreement with HealthCare Royalty Pharmosa to receive up to $215 million in development and sales milestones for PAH and PH-ILD indications, […]
Microbot Medical Raises a Total of $7.6 Million in Gross Proceeds from Four Recent Registered Direct Offerings
Microbot Medical Closes Fourth Registered Direct Offering Priced At-The-Market under Nasdaq Rules HINGHAM, Mass., June 28, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) today announced that it closed its previously announced registered direct offering for the purchase and sale of 624,618 shares of the Company’s common stock at […]
Eko Health Launches CORE 500™ Digital Stethoscope with Heart Disease Detection AI, 3-Lead ECG, and Advanced Audio Capabilities
Next-generation FDA-cleared medical device brings non-invasive heart and lung disease detection to healthcare professionals at the point of care EMERYVILLE, Calif., June 27, 2023 /PRNewswire/ — Eko Health, a leading innovator in digital health technology for heart and lung disease detection, today announced the launch of its next-generation digital stethoscope, CORE 500™. The CORE […]
Boston Scientific Elects Dr. Jessica L. Mega and Susan E. Morano to Board of Directors
MARLBOROUGH, Mass., June 27, 2023 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Jessica L. Mega and Susan E. Morano to its board of directors, each effective immediately. Dr. Mega is the co-founder of Verily Life Sciences LLC, a subsidiary of Alphabet Inc. focused on life sciences and healthcare, and was the […]
Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors
WARRINGTON, Pa., June 27, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the Company appointed Mark Strobeck, Ph.D. to its Board of Directors. Dr. Strobeck has more than 20 years of […]
BioSig Advances Collaboration on Machine Learning and Artificial Intelligence Solutions for Healthcare
Westport, CT, June 27, 2023 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it is advancing the research and development of an artificial intelligence (AI) medical device platform in collaboration […]
Microbot Medical Announces $2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
HINGHAM, Mass., June 27, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 624,618 shares of the Company’s common stock at a purchase price of $3.25 per share of common stock in a registered direct […]
Bristol Myers Squibb Receives European Commission Approval of CAMZYOS® (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
CAMZYOS is the first and only cardiac myosin inhibitor approved in the European Union Approval based on two positive Phase 3 trials, EXPLORER-HCM and VALOR-HCM, demonstrating significant benefit in patients treated with CAMZYOS versus placebo PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved CAMZYOS® (mavacamten, 2.5 mg, 5 […]
MicroVention Reshapes Stroke Therapy with the Introduction of the ERIC™ Retrieval Device; ERIC Delivers Thrombus Control, Procedure Efficiency and Versatility When Every Second Counts
MicroVention Now Offers a Fully Integrated, Comprehensive Stroke Portfolio, Delivering Breakthrough Innovation from Access to Revascularization ALISO VIEJO, Calif.–(BUSINESS WIRE)–MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today announced that the ERIC Retrieval Device is now commercially available in the United States for ischemic stroke treatment. ERIC received […]



